Moreover, the 36-month beta value for NRSN is 1.49. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NRSN is 14.55M and currently, short sellers hold a 2.63% of that float. On November 21, 2024, NRSN’s average trading volume was 238.10K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NRSN) stock’s latest price update
NeuroSense Therapeutics Ltd (NASDAQ: NRSN)’s stock price has dropped by -11.20 in relation to previous closing price of 1.12. Nevertheless, the company has seen a loss of -25.56% in its stock price over the last five trading days. prnewswire.com reported 2024-10-28 that Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026 CAMBRIDGE, Mass. , Oct. 28, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd.
NRSN’s Market Performance
NeuroSense Therapeutics Ltd (NRSN) has seen a -25.56% fall in stock performance for the week, with a -13.90% decline in the past month and a 19.72% surge in the past quarter. The volatility ratio for the week is 9.10%, and the volatility levels for the past 30 days are at 8.53% for NRSN. The simple moving average for the past 20 days is -21.19% for NRSN’s stock, with a -18.54% simple moving average for the past 200 days.
NRSN Trading at -19.58% from the 50-Day Moving Average
After a stumble in the market that brought NRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.51% of loss for the given period.
Volatility was left at 8.53%, however, over the last 30 days, the volatility rate increased by 9.10%, as shares sank -13.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.84% lower at present.
During the last 5 trading sessions, NRSN fell by -25.56%, which changed the moving average for the period of 200-days by -22.65% in comparison to the 20-day moving average, which settled at $1.2563. In addition, NeuroSense Therapeutics Ltd saw 26.13% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NRSN
The total capital return value is set at 7.32. Equity return is now at value -602.40, with -173.59 for asset returns.
Currently, EBITDA for the company is -10.63 million with net debt to EBITDA at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.46.
Conclusion
To wrap up, the performance of NeuroSense Therapeutics Ltd (NRSN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
